REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.
Ghorani E, Quartagno M, Blackhall F, Gilbert DC, O'Brien M, Ottensmeier C, Pizzo E, Spicer J, Williams A, Badman P, Parmar MKB, Seckl MJ; REFINE-Lung Investigators.
Ghorani E, et al. Among authors: williams a.
Lancet Oncol. 2023 May;24(5):e219-e227. doi: 10.1016/S1470-2045(23)00095-5.
Lancet Oncol. 2023.
PMID: 37142383
Review.